Immunovant (IMVT) Q4 2026 earnings review
A Clean Slate: Batoclimab Dead, All Eyes on IMVT-1402
Immunovant is officially a single-asset company again. Following dual Phase 3 failures in Thyroid Eye Disease (TED), management decisively killed the entire batoclimab program, taking a $39M wind-down charge that drove Q4 net loss to $147.9M. The silver lining is a massive pivot to the next-gen FcRn inhibitor, IMVT-1402, which just posted exceptional proof-of-concept data in difficult-to-treat Rheumatoid Arthritis (D2T RA) with a 72.7% ACR20 response rate. Backed by a $902M cash fortress, the company is fully funded through the 2027 Graves' disease readouts, but the margin for error has evaporated—the entire valuation now rests on IMVT-1402's shoulders.
🐂 Bull Case
The Phase 2 Period 1 data in D2T RA is highly encouraging. Achieving a 72.7% ACR20 and 54.5% ACR50 in a heavily pre-treated population (mean 12.8 years since diagnosis, failed multiple advanced therapies) validates 1402's efficacy profile.
Thanks to a $550M raise in Q3, Immunovant sits on $902.1M in cash. This removes near-term dilution risk and provides a clear runway through the pivotal 2027 readouts for Graves' Disease (GD) and Myasthenia Gravis (MG).
🐻 Bear Case
With batoclimab completely discontinued, Immunovant has zero backup plans. If IMVT-1402 encounters safety signals or trial failures in upcoming pivotal readouts, the company's core value proposition collapses.
The failure of batoclimab in two Phase 3 TED trials raises questions about the broader application of FcRn inhibitors in certain autoimmune conditions, requiring investors to scrutinize 1402's indication selection.
⚖️ Verdict: ⚪
Neutral. The decisive cut of batoclimab was painful but necessary, clearing the deck for a superior molecule. The IMVT-1402 RA data is undeniably strong, but absorbing a $39M charge to consolidate into a single-asset pipeline inherently spikes the risk profile. It's a binary waiting game for 2027.
Key Themes
Batoclimab Discontinuation Cost and Impact
After two Phase 3 trials in TED missed their primary endpoints, management made the hard pivot to discontinue batoclimab across all indications. This triggered $39.0M in contractual costs, inflating Q4 R&D expenses by 52% YoY. While abandoning a flawed legacy asset saves future cash burn, it highlights the high attrition risk in immunology and strips the company of its most advanced pipeline candidate.
IMVT-1402 Validated in Refractory RA
The preliminary 16-week open-label data for IMVT-1402 in difficult-to-treat Rheumatoid Arthritis (D2T RA) provides a major de-risking event. In a cohort where 86.7% of patients had failed at least two prior advanced therapies, 1402 delivered observed ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8%. Notably, among patients who previously failed both a JAK and anti-TNF inhibitor, efficacy held steady (72.0% ACR20). No new safety signals were identified, reinforcing the clean profile of simple subcutaneous dosing.
Cash Fortress Secures Operations Through 2027
Immunovant's liquidity position is stable and robust. After executing a $550M financing in Q3, the company ended FY26 with $902.1M in cash. Despite the elevated Q4 burn from the batoclimab write-off, this balance guarantees the runway needed to fund the pivotal IMVT-1402 programs in GD and MG straight through to their expected readouts in 2027, removing near-term capital markets risk.
G&A Expense Discipline
While R&D spending is accelerating aggressively to support late-stage trials, management is showing operational leverage in General & Administrative costs. G&A actually decelerated in Q4, falling to $17.3M from $20.2M a year ago, driven by lower IT, market research, and legal fees. Full-year G&A was essentially flat YoY at $76.2M vs $77.2M, ensuring that capital is efficiently funneled directly into clinical development.
Other KPIs
Accelerating significantly from $360.9M in FY25. This $95.8M increase reflects the aggressive scale-up of IMVT-1402 trials (contract manufacturing and personnel), plus the $39M one-time hit from killing batoclimab. Excluding stock-based compensation, non-GAAP R&D was $426.9M.
Widening from $413.8M in FY25. The loss equates to $2.77 per share. Stock-based compensation accounted for $55.7M of this loss. Despite the ballooning deficit, interest income on their massive cash pile provided a $25.3M offset during the year.
Guidance
Topline data from the fully enrolled proof-of-concept trial is expected in the second half of 2026. This will be the next major catalyst to validate 1402 outside of RA.
Additional data from the ongoing D2T RA study (which is moving into its blinded, randomized Period 2 phase assessing ACR20 maintenance at Week 28) will be released in the second half of the year.
Topline data for the potentially registrational trials in Graves' Disease and Myasthenia Gravis are slated for 2027. This represents the ultimate binary event for the company's valuation.
Key Questions
Batoclimab R&D Run-Rate Savings
With batoclimab discontinued and the $39M wind-down charge booked, what is the expected reduction in quarterly baseline R&D spend, and how quickly will the IMVT-1402 scale-up offset those savings?
TED Failure Read-Through
What specific mechanistic or trial-design learnings from the batoclimab Thyroid Eye Disease failure are being applied to IMVT-1402 to ensure we don't see a repeat failure in Graves' Disease or other indications?
D2T RA Period 2 Expectations
Given the 72.7% ACR20 response rate at Week 16, what level of maintenance or drop-off are you modeling for the Week 28 primary endpoint during the blinded Period 2 phase?